NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.2 Drugs affecting the immune response > 8.2.3 Anti-lymphocyte monoclonal antibodies > Leukaemia (chronic lymphocytic, first line) - rituximab - NICE TAG TA174

Leukaemia (chronic lymphocytic, first line) - rituximab - NICE TAG TA174

1.1 Rituximab in combination with fludarabine and cyclophosphamide is recommended as an option for the first-line treatment of chronic lymphocytic leukaemia in people for whom fludarabine in combination with cyclophosphamide is considered appropriate.

1.2 Rituximab in combination with chemotherapy agents other than fludarabine and cyclophosphamide is not recommended for the first-line treatment of chronic lymphocytic leukaemia.

 

https://www.nice.org.uk/guidance/TA174

Site by Devopa
© Copyright 2019 NHS. All rights reserved.